Fig. 3: Clozapine and olanzapine concentration/dose ratios in the <10th (slow metabolism), [10-90th] (normal metabolism) and >90th percentiles (fast metabolism) of caffeine metabolic ratios. | Molecular Psychiatry

Fig. 3: Clozapine and olanzapine concentration/dose ratios in the <10th (slow metabolism), [10-90th] (normal metabolism) and >90th percentiles (fast metabolism) of caffeine metabolic ratios.

From: Dietary caffeine to assess CYP1A2 activity, tailor clozapine doses, and predict treatment response: genetic, epigenetic and clinical analyses

Fig. 3

The p-values were obtained by fitting linear mixed-effects models. Boxplots display dose-adjusted plasma concentrations of clozapine (top) and olanzapine (bottom) stratified by caffeine metabolic ratio percentiles (< p10, [p10–p90], >p90). For Clozapine: • <p10 (n = 17): Median = 1.48 ng/mL/mg; IQR = 1.52 (Q1 = 0.95, Q3 = 2.47).• [p10–p90] (n = 130): Median = 1.13 ng/mL/mg; IQR = 0.76 (Q1 = 0.79, Q3 = 1.6).• >p90 (n = 17): Median = 0.53 ng/mL/mg; IQR = 0.39 (Q1 = 0.39, Q3 = 0.78). For Olanzapine: • <p10 (n = 23): Median = 2.57 ng/mL/mg; IQR = 1.85 (Q1 = 1.92, Q3 = 3.77).• [p10–p90] (n = 176): Median = 2.12 ng/mL/mg; IQR = 1.43 (Q1 = 1.5, Q3 = 2.93).• >p90 (n = 23): Median = 1.5 ng/mL/mg; IQR = 0.88 (Q1 = 0.99, Q3 = 1.88).

Back to article page